Each year, Frost & Sullivan presents its Global Product Leadership Award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.
In its analysis, Frost & Sullivan also noted the significant flexibility of the I2E platform which can be applied across a variety of applications such as gene-disease mapping and target identification, biomarker discovery, regulatory compliance management, drug safety, clinical trial analysis, drug patent landscape reporting and analysis, real-world data analysis, and identification of clinical care gaps. This wide applicability facilitates a higher return on investment (ROI) for clients looking to adopt the platform at the enterprise level. The solution is already being used by 18 of the top 20 pharmaceutical companies and a large number of oncology research organizations.
Download the full report to learn more.
"Linguamatics' solution combines enterprise, cloud-based, and hybrid implementation models, offering end users an integrated view for faster and well-informed decision-making,” noted Behera. “This type of platform flexibility is unique and helps Linguamatics deploy innovative solutions in clinical development and translational research environments. For its user-friendly, innovative text mining platform that has helped clients process unstructured data in many contexts, Linguamatics richly deserves Frost & Sullivan's 2018 Global Product Leadership Award.”
Questions? Ask our experts